Discontinued — last reported Q2 '18
Deferred Tax Assets
Vertex Pharmaceuticals Deferred Tax Assets decreased by 1.3% to $2.90B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 24.3%, from $2.33B to $2.90B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 26.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests potential future tax savings, while a decrease may indicate the utilization of these assets or valuation allowances.
Detailed definition
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between acc...
Peer comparison
Standard accounting item for large corporations with complex tax structures and international operations.
deferred_tax_assetsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $952.81M | $933.84M | $934.50M | $945.50M | $1.14B | $1.16B | $1.25B | $1.36B | $1.54B | $1.73B | $1.81B | $1.96B | $2.19B | $2.31B | $2.33B | $2.54B | $2.71B | $2.94B | $2.90B |
| QoQ Change | — | -2.0% | +0.1% | +1.2% | +21.0% | +1.7% | +7.2% | +9.1% | +13.1% | +12.4% | +4.8% | +8.3% | +11.3% | +5.6% | +1.0% | +9.1% | +6.6% | +8.3% | -1.3% |
| YoY Change | — | — | — | — | +20.0% | +24.5% | +33.4% | +43.8% | +34.5% | +48.7% | +45.3% | +44.3% | +42.1% | +33.5% | +28.6% | +29.6% | +24.1% | +27.2% | +24.3% |
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred tax assets?
- Vertex Pharmaceuticals (VRTX) reported deferred tax assets of $2.90B in Q4 2025.
- How has Vertex Pharmaceuticals's deferred tax assets changed year-over-year?
- Vertex Pharmaceuticals's deferred tax assets increased by 24.3% year-over-year, from $2.33B to $2.90B.
- What is the long-term trend for Vertex Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's deferred tax assets has grown at a 26.8% compound annual growth rate (CAGR), from $882.78M to $2.90B.
- What does deferred tax assets mean?
- Future tax benefits that the company expects to realize.